Page 1

DiaSorin The Diagnostic Specialist - DIASORIN 2022-2025 STRATEGIC PLAN : SPECIALIST³ " The Strategic Plan approved today by the Board of Directors outlines the strategies that will drive the evolution of DiaSorin in the coming years . The completion of current strategic projects and the launch of new initiatives will enable and support growth over the next several years , while also leveraging the new competencies acquired through the acquisition of Luminex " , commented Carlo Rosa , CEO of DiaSorin . " In the last two years , the pandemic has redefined the role of diagnostics in public health management and has posed new challenges for national health systems to which DiaSorin intends to respond by strengthening its position as a Specialist < cubed > " . GUIDANCE 2022-2025 AT CONSTANT EXCHANGE RATES¹ : REVENUE : PRESS RELEASE 2021-2022 : EX - COVID REVENUE GROWTH OF APPROX . 24 % ; APPROX . -2 % INCLUDING COVID RELATED REVENUE 2022-2025 : EX - COVID REVENUE GROWTH OF 10 % CAGR ; APPROX . + 7 % CAGR INCLUDING COVID RELATED REVENUE ADJUSTED EBITDA² MARGIN : 2022 : APPROX . 35 % 2025 : APPROX . 38 % , IN LINE WITH PRE - PANDEMIC AND PRE - LUMINEX ACQUISITION MARGIN GROWTH DRIVERS : START OF NEW " VALUE BASED CARE " PROGRAMS IN IMMUNODIAGNOSTICS AND FURTHER EXPANSION OF SPECIALTY MENU LAUNCH OF NEW MOLECULAR DIAGNOSTIC AND LICENSED TECHNOLOGIES PLATFORMS MOLECULAR DIAGNOSTIC AND LICENSED TECHNOLOGIES BUSINESS INTEGRATION FURTHER PENETRATION OF THE U.S. MARKET COST AND REVENUE SYNERGIES GENERATED THROUGH LUMINEX INTEGRATION EQUAL TO APPROX . USD 90 MILLION IN 2025 CUMULATIVE FREE CASH FLOW GENERATION OF APPROX . € 1.1 BILLION IN 2022-2025 SIGNIFICANT REDUCTION OF THE NET DEBT - TO - ADJUSTED EBITDA² RATIO FROM APPROX . 1.9X IN 2021 TO APPROX . 0.5X IN 2025 PROJECT APPROVAL FOR THE REDEFINITION OF THE DIASORIN CORPORATE STRUCTURE ¹ In order to allow comparability across years , all financial data has been restated at constant exchange rate ( with regards to the US Dollar 1.16 US $ per EUR ) 2 Adjusted EBITDA = EBITDA , excluding extraordinary costs and expenses incurred in the Luminex transaction announced on April 11 , 2021 1